Drugs / modified Shenling Baizhu San
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05122702 | Jul 2022 → Jul 2024 | macular retinal edema | Chinese University of Hong Kong | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | modified Shenling Baizhu San | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05122702 ↗ |
| Known as | mSBS | “evaluate the efficacy and safety of modified SBS (mSBS) developed by the project team for the treatment of ME.” NCT05122702 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “This study is of an innovative Chinese herbal formula modified from a famous ancient formula for the treatment of macular edema.” NCT05122702 ↗ |
| Route | Oral | “Eligible subjects will be recruited and assigned randomly to receive orally mSBS or placebo twice a day for 12 consecutive weeks” NCT05122702 ↗ |